Journal for immunotherapy of cancer · 2026
Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Jing, Yuan Xiaolong, Yu Haiyang, Liu Ziqi, Chen Shi, Zhu Fang, Shang Yuhua, Hong Shikai, Han Xinghua, Zhu Zhengzhi, Jin Tengchuan, Pan Yueyin, Zhou Shoubing
Аннотация
BACKGROUND: The immunologically "cold" microenvironment of triple-negative breast cancer presents a major obstacle to treatment, conferring resistance to current immunotherapies. Targeting the stimulator of interferon genes (STING) pathway has emerged as a promising strategy to enhance immunotherapy efficacy.
METHODS: In this preclinical study, we leveraged a novel integrated approach by employing a B7-H3-targeted dual-payload antibody-drug conjugate (ADC) to induce innate immune responses and reprogram the tumor microenvironment.
RESULTS: Our preliminary results indicated that the dual-payload ADC induces immunogenic cell death, leading to the release of double-stranded DNA and subsequent activation of the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase-STING pathway in macrophages and dendritic cells. This, in turn, promotes dendritic cell maturation, M1 macrophage polarization, and enhanced T-cell infiltration, effectively converting immunologically "cold" tumors into "hot" ones. Most importantly, the synergistic combination of the dual-payload ADC with immune checkpoint inhibitors (PD-L1 and 4-1BB) not only rapidly bridges innate and adaptive immunity but also elicits a robust long-term immune memory response.
CONCLUSIONS: Collectively, these preliminary results demonstrate that the antitumor efficacy of the dual-payload ADC is mediated through STING pathway activation. This insight opens new avenues for enhancing immunotherapy in B7-H3-expressing solid tumors and paves the way for the clinical translation of next-generation ADC designs.
METHODS: In this preclinical study, we leveraged a novel integrated approach by employing a B7-H3-targeted dual-payload antibody-drug conjugate (ADC) to induce innate immune responses and reprogram the tumor microenvironment.
RESULTS: Our preliminary results indicated that the dual-payload ADC induces immunogenic cell death, leading to the release of double-stranded DNA and subsequent activation of the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase-STING pathway in macrophages and dendritic cells. This, in turn, promotes dendritic cell maturation, M1 macrophage polarization, and enhanced T-cell infiltration, effectively converting immunologically "cold" tumors into "hot" ones. Most importantly, the synergistic combination of the dual-payload ADC with immune checkpoint inhibitors (PD-L1 and 4-1BB) not only rapidly bridges innate and adaptive immunity but also elicits a robust long-term immune memory response.
CONCLUSIONS: Collectively, these preliminary results demonstrate that the antitumor efficacy of the dual-payload ADC is mediated through STING pathway activation. This insight opens new avenues for enhancing immunotherapy in B7-H3-expressing solid tumors and paves the way for the clinical translation of next-generation ADC designs.